Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -36114.03% is 45763% below its 1-year average of -78.74%, near the low end of its 1-year range (-36114.03%–-62.18%).
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q1 FY2026 (2026-03-31): -90.92%.
RETURN ON EQUITY (ROE)
-36114.03%
RETURN ON EQUITY (ROE) AVG TTM
N/A
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-41.15%
median of 712 covered companies
CURRENT VS SECTOR MEDIAN
-87661.92%
vs the sector median at left
NOMAD Power Solutions, Inc.
Market Cap
$52.27M
Return on Equity (ROE)
-36114.03%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$49.77M
Return on Equity (ROE)
-52.72%
TTM Avg
-32.48%
3Y Avg
-92.81%
5Y Avg
-85.98%
Market Cap
$52.66M
Return on Equity (ROE)
-60.85%
TTM Avg
-77.57%
3Y Avg
-56.89%
5Y Avg
-53.13%
Market Cap
$51.61M
Return on Equity (ROE)
-76.82%
TTM Avg
-798.41%
3Y Avg
-485.96%
5Y Avg
-324.45%
Market Cap
$52.27M
Return on Equity (ROE)
N/A
TTM Avg
-24.59%
3Y Avg
-14.57%
5Y Avg
93.61%
Market Cap
$51.42M
Return on Equity (ROE)
-278.89%
TTM Avg
-162.92%
3Y Avg
25.71%
5Y Avg
0.37%
Market Cap
$50.95M
Return on Equity (ROE)
-708.48%
TTM Avg
156.13%
3Y Avg
510.26%
5Y Avg
342.91%
Market Cap
$53.63M
Return on Equity (ROE)
-36.94%
TTM Avg
-31.55%
3Y Avg
-37.51%
5Y Avg
-20.44%
Market Cap
$50.80M
Return on Equity (ROE)
-57.10%
TTM Avg
-36.66%
3Y Avg
-227.16%
5Y Avg
-314.45%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NOMAD Power Solutions, Inc. (NMAD) | $52.27M | -36114.03% | N/A | N/A | N/A |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $49.77M | -52.72% | -32.48% | -92.81% | -85.98% |
| Aldeyra The (ALDX)vs › | $52.66M | -60.85% | -77.57% | -56.89% | -53.13% |
| Rani Therapeutics Holdings, Inc. (RANI)vs › | $51.61M | -76.82% | -798.41% | -485.96% | -324.45% |
| biote Corp. (BTMD)vs › | $52.27M | N/A | -24.59% | -14.57% | 93.61% |
| eXoZymes, Inc. (EXOZ)vs › | $51.42M | -278.89% | -162.92% | 25.71% | 0.37% |
| Envoy Medical, Inc. (COCH)vs › | $50.95M | -708.48% | 156.13% | 510.26% | 342.91% |
| ImageneBio Inc (IMA)vs › | $53.63M | -36.94% | -31.55% | -37.51% | -20.44% |
| Tenax Therapeutics, Inc. (TENX)vs › | $50.80M | -57.10% | -36.66% | -227.16% | -314.45% |
| Clene Inc. (CLNN)vs › | $50.61M | N/A | 296.81% | -175.08% | -1071.79% |
ROE
-36114.0%
ROA
-32404.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-03-31 | -90.92% |
| 2025-12-31 | -62.18% |
| 2025-09-30 | -83.13% |
